首页 > 用药指导 > 文章详情

Baricitinib(艾乐明)的不良反应

发布时间:2024-02-21 13:40:33 阅读:1404 来源:问药网
分享至

分享到微信朋友圈

×

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

巴瑞替尼片

巴瑞替尼片 生产厂家:孟加拉碧康制药股份有限公司 功能主治:对一种或多种抗风湿药物缓解不足或不耐受的中度至重 用法用量:用法用量  1、类风湿性关节炎  OLUMIANT的推荐剂量为每日1次口服2mg,餐前餐后都可。  OLUMIANT可以单独使用,也可以与甲氨蝶呤或其他非生物dmard联合使用。  2、COVID-19(新冠病毒)  成人OLUMIANT的推荐剂量为每日一次口服4mg,餐前餐后都可,持续14天或直到出院,以先发生者为准。  3、斑秃  OLUMIANT的推荐剂量是2mg,每天一次口服,餐前餐后都可。  如果对治疗的反应不充分,增加到每天一次4mg。  对于几乎完全或完全的头皮脱发,睫毛或眉毛有或没有大量脱发的患者,考虑每天一次4mg治疗,伴餐前餐后都可。  一旦患者对4mg的治疗产生了充分的反应,将剂量减少到2mg,每天一次。  对于无法吞下整片药片的患者,可以考虑另一种给药方式:  1、口服分散  2、胃造口管(G管)  3、鼻胃管(NG管)或口胃管(OG管)
查看详情

Baricitinib(艾乐明)的不良反应,Baricitinib(Baricitinib)常见副作用有:1、严重感染,如肺炎、带状疱疹和尿路感染;2、死亡率,50岁以上及有心血管疾病的患者有更高的全因死亡率;3、恶性肿瘤和淋巴增生性疾病;4、重大心血管不良事件;5、血栓形成;6、会出现过敏反应;7、胃肠道穿孔;8、可能会对胎儿造成损害。

Baricitinib (艾乐明) is a medication used for the treatment of rheumatoid arthritis, COVID-19, and alopecia areata. While it has proven to be effective in managing these conditions, like any medication, it is associated with certain adverse reactions. In this article, we will explore the potential adverse effects of Baricitinib and discuss them in detail.

1. Gastrointestinal Adverse Reactions:

Gastrointestinal adverse reactions are among the common side effects of Baricitinib. They may include symptoms such as nausea, diarrhea, and abdominal pain. In some cases, these symptoms may be mild and transient, while in others, they may persist or worsen. It is important to inform your healthcare provider if you experience any persistent or severe gastrointestinal symptoms while taking Baricitinib.

2. Increased Risk of Infections:

Baricitinib can suppress the immune system, which may lead to an increased risk of infections. The medication works by inhibiting certain enzymes in the body that are involved in inflammatory processes. While this reduces inflammation, it can also weaken the body's ability to fight off infections. Patients taking Baricitinib should be cautious about the signs of infection, such as fever, cough, or urinary tract symptoms, and promptly seek medical attention if any such symptoms develop.

3. Potentially Serious Infections:

In rare cases, Baricitinib may be associated with serious infections that may require hospitalization or lead to severe complications. These infections can include bacterial, viral, or fungal infections, such as pneumonia or cellulitis. Patients should be aware of the signs of serious infections, like high fever, severe fatigue, and difficulty breathing, and seek immediate medical care if these symptoms occur.

4. Blood Clotting Disorders:

Another potential adverse reaction of Baricitinib is an increased risk of blood clotting disorders. This may manifest as deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial thrombosis. Symptoms may include swelling in the legs, chest pain, shortness of breath, or sudden onset of weakness or numbness in the limbs. Patients should inform their healthcare provider promptly if they develop any of these symptoms.

5. Elevated Liver Enzymes:

Baricitinib has been associated with elevated liver enzymes in some patients. This may indicate liver dysfunction and can be detected through routine blood tests. Regular monitoring of liver function is therefore necessary while taking Baricitinib to ensure early detection of any potential liver problems.

It is important to note that the above adverse reactions are not exhaustive, and there may be other potential side effects associated with Baricitinib. It is crucial to consult with a healthcare professional before starting this medication, carefully consider the risks and benefits, and discuss any concerns or pre-existing conditions that may affect its safe use.

In conclusion, while Baricitinib can be an effective treatment for rheumatoid arthritis, COVID-19, and alopecia areata, it is important to be aware of its potential adverse reactions. Gastrointestinal symptoms, increased risk of infections, serious infections, blood clotting disorders, and elevated liver enzymes are among the possible side effects associated with this medication. Regular monitoring and open communication with your healthcare provider can help ensure safe and appropriate use of Baricitinib.